Denali remains on track to submit a BLA for tividenofusp alfa or DNL310 for the treatment of MPS II (Hunter syndrome), under the accelerated approval pathway in early 2025, and is preparing for a ...
Children with Hunter syndrome have a missing gene ... Following successful engraftment of modified HSCs in the bone marrow, these cells start to produce daughter blood cells which contain the IDS gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback